Opdualag vs. cemiplimab/fianlimab for melanoma
Part of Cancer clinical trials.
This trial compares two treatments for advanced melanoma that cannot be removed with surgery or has spread. It studies how these treatments affect the immune response in tumors and blood, and requires extra biopsies and blood draws.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be eligible for another study called HCC 24-056.
- You need to give 3 extra tumor samples (biopsies) during the study.
- You need to give 3 extra blood samples.
- You must have a tumor that can be safely biopsied at least 3 times.
- You must be able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This study checks on the long-term health of adults with melanoma who took part in a previous treatment study. It aims to see how participants are doing over time after receiving the new therapy.
This study tests different ways of using the drug cemiplimab to treat advanced basal cell skin cancer that cannot be removed with surgery or treated with radiation. It aims to find the most effective approach to shrink or control the cancer.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. The drugs are given to boost your immune system to attack the cancer before it's removed.
This trial tests two drugs, cemiplimab and ziv-aflibercept, together for people whose uveal melanoma has spread. It may be an option if previous treatments have stopped working or you haven't had treatment yet.
Hear when a new Locally Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.